Question follow-through · 41684

Innovative Medicines Fund

To ask the Secretary of State for Health and Social Care, if his Department will make an assessment of the (a) adequacy of the entry criteria for the Innovative Medicines Fund and (b) whether these present barriers to patients accessing medicines in areas

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
26 Mar 2025
Target answer date
31 Mar 2025
Answer
31 Mar 2025 · 5 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

More questions by this MP on Health and care

Shared topic keywords suggest a connection; they do not establish a follow-up.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 26 Mar 2025

    Question tabled

    To ask the Secretary of State for Health and Social Care, if his Department will make an assessment of the (a) adequacy of the entry criteria for the Innovative Medicines Fund and (b) whether these present barriers to patients accessing medicines in areas

  2. 31 Mar 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 31 Mar 2025

    Answer published

    The Innovative Medicines Fund (IMF) was launched in June 2022, building on the successful Cancer Drugs Fund and supporting patient access to the most promising new medicines while further evidence is collected on their use to address clinical uncertainty....

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Pharmacy: Finance

27 Mar 2025 · To ask the Secretary of State for Health and Social Care, whether his Department has plans to link pharmacy funding to inflation and National Living Wage increases.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Pharmacy: Finance

27 Mar 2025 · To ask the Secretary of State for Health and Social Care, if he will made an assessment of the potential merits of increasing the length of funding periods of pharmacies.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

NHS England

31 Mar 2025 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of closing NHS England on the (a) timeline for the production of the NHS 10-year plan and (b) publication date of that plan.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

NHS: Databases

31 Mar 2025 · To ask the Secretary of State for Health and Social Care, if he will consider the final costs and benefits statement for programmes delivered under the National Programme of Technology, published on 6 June 2013, in his plans for (a) an NHS Federated Data

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Dementia: Research

1 Apr 2025 · To ask the Secretary of State for Health and Social Care, how much funding was allocated to dementia research by (a) the National Institute for Health and Care Research, (b) UK Research and Innovation and (c) other public bodies in each of the last five y

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Dementia: Clinical Trials

1 Apr 2025 · To ask the Secretary of State for Health and Social Care, how many phase (a) one, (b) two and (c) three dementia clinical trials there have been in the UK in each of the last ten years; and how many participants were recruited for each of those trials.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Pharmacy

17 Apr 2025 · To ask the Secretary of State for Health and Social Care, when he plans to publish the report on economic review into community pharmacy.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Spinal Muscular Atrophy: Babies

24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the UK National Screening Committee on timelines for implementing in-service evaluation of newborn screening for spinal muscular atrophy.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Spinal Muscular Atrophy: Babies

24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what information the UK National Screening Committee has provided on the (a) format, (b) scale and (c) duration of the upcoming in-service evaluation of newborn screening for Spinal Muscular Atroph

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Spinal Muscular Atrophy: Babies

24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching newborn screening for Spinal Muscular Atrophy alongside the upcoming launch of newborn screening for severe combined immunodeficienc

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Hormone Replacement Therapy

7 May 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on the adequacy of

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Hormone Replacement Therapy

7 May 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on the adequacy of